Calidi Biotherapeutics, Inc. financial data

Symbol
CLDI on NYSE, CLDWW on OTC
Location
San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % +652%
Debt-to-equity 199 %
Return On Equity -432 % -282%
Return On Assets -152 % +55.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.17M shares -45.2%
Common Stock, Shares, Outstanding 6.91M shares -25.8%
Entity Public Float 14M USD -67.6%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 4.91K shares
Weighted Average Number of Shares Outstanding, Diluted 4.91K shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.19M USD -16.6%
Operating Income (Loss) -19.8M USD +28.2%
Nonoperating Income (Expense) -332K USD -126%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.1M USD +23.4%
Income Tax Expense (Benefit) 20K USD +150%
Net Income (Loss) Attributable to Parent -20M USD +23.8%
Earnings Per Share, Basic 19 USD/shares +71.5%
Earnings Per Share, Diluted 19 USD/shares +71.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.6M USD
Accounts Receivable, after Allowance for Credit Loss, Current 870 USD
Assets, Current 11M USD +397%
Property, Plant and Equipment, Net 849K USD -13.5%
Operating Lease, Right-of-Use Asset 2.01M USD -37.8%
Other Assets, Noncurrent 140K USD -35.5%
Assets 14M USD +111%
Accounts Payable, Current 487K USD +1652%
Accrued Liabilities, Current 5.79M USD +1574%
Liabilities, Current 5.19M USD -55.2%
Operating Lease, Liability, Noncurrent 640K USD -70.4%
Other Liabilities, Noncurrent 1.5M USD
Liabilities 6.83M USD -58.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -13K USD +82.4%
Retained Earnings (Accumulated Deficit) -138M USD -17%
Stockholders' Equity Attributable to Parent 6.92M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 7.2M USD
Liabilities and Equity 14M USD +111%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.13M USD -86.1%
Net Cash Provided by (Used in) Financing Activities 8.11M USD +169%
Net Cash Provided by (Used in) Investing Activities -7K USD -40%
Common Stock, Shares Authorized 330M shares 0%
Common Stock, Shares, Issued 6.91M shares -25.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 970K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.6M USD +401%
Interest Paid, Excluding Capitalized Interest, Operating Activities 639K USD +2563%
Deferred Tax Assets, Valuation Allowance 29.4M USD +23.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 30.2M USD +20.9%
Operating Lease, Liability 1.99M USD -40%
Depreciation 391K USD -2.49%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.9M USD +24.5%
Lessee, Operating Lease, Liability, to be Paid 2.18M USD -43%
Property, Plant and Equipment, Gross 2.56M USD +12.2%
Operating Lease, Liability, Current 1.35M USD +16.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 295K USD -80.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.51M USD +6.03%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 184K USD -63.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2K USD -99.6%
Deferred Tax Assets, Operating Loss Carryforwards 20.2M USD +32.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 1.8M USD +18.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2K USD -99.6%
Operating Lease, Payments 362K USD +3.73%
Additional Paid in Capital 144M USD +34.5%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.29M USD -35%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%